diego duarte alcoba, ph.d. - jotatec and stroke... · documento classificado como...

Documento classificado como "1-Público" / Document marked "1-Public"

Diego Duarte Alcoba, Ph.D.

Consultor Científico, Daiichi-Sankyo

Porto Alegre, 16 de novembro de 2016

IntroductionSubclinical AF


� ¼ of ischemic strokes are of unknown cause

(undiagnosed AF may be a potential etiologic factor);

� While AF typically presents with palpitations,

dyspnea, chest pain, and fatigue, it may also be

asymptomatic

� Asymptomatic episodes of AF

- AHREs: atrial high-rate episodes (> 5 / 6 min.)

Such patients are at elevated risk of

stroke and may have unmet anticoagulation needs!

Camm J et al., European Society of Cardiology. 2016


IntroductionCurrent strategies for stroke prevention in atrial fibrillation

� The effectiveness and safety of NOACs in patients with AHRE/subclinical

AF (SCAF) but without ECG documented AF is unknown.

� If it were demonstrated that NOACs provide a clinical benefit in such

patients, potential stroke prevention could be improved, given that these

patients represent a high percentage of patients with cardiac rhythm

management devices.



IntroductionIncidence of atrial high-rate events



IntroductionAtrial high-rate episode and stroke risk





The annualized TE risk (including TIA) was 1.1% for zero, 1.1% for low, and

2.4% for high AT burden.




Subclinical AF was…

detected in 10.1% patients within 3 months of device implantation.

associated with an increased risk of clinical AF and of ischemic

stroke or SE.

The presence of SCAF was predictive of stroke or SE even after adjustment

for predictors of stroke.




Other studies have also added to the body of evidence for the association between AHREs and stroke.


IntroductionImplications of study findings on atrial high-rate episodes and stroke risk


� It is possible than rather than causing embolic events, AHRE are simply a

marker for cardio-embolic risk;

� The occurrence of AHRE may trigger chronic changes in the atria that result

in thrombus formation after the occurrence of SCAF.


IntroductionImplications for clinical practice


� Study findings have indicated that patients experiencing AHRE are at elevated

risk for stroke, TIA, and SE and raise the question…

…should these patients receive oral anticoagulation therapy for stroke

prevention?

While the data from MOST, TRENDS, and ASSERT support a link

between pacemaker-AHRE and the occurrence of stroke or SE,

these studies are limited by their small sample size and limited

number of clinical events.

NNNNon-vitamin K antagonist OOOOral anticoagulants

in patients with AAAAtrial HHHHigh rate

episodes (NOAH – edoxabana fase IIIb)


AAS 100mg ou placebo (escolha do ivnestigador)

EDOXABANA 60/30mg(30 mgse CrCl 30-50mL/min, peso <60kg, uso

de inibidor da PgP

PATIENTES• idade ≥ 65ª

• Episódio de ritmo atrial elevado (≥180 bpm e ≥6 min de

duração) detectado por marcapasso/CDI

• CHA2DS2VASc ≥ 2

• EXCLUSÃO: História de FA/flutter atrial

N=3400

Conclusão Set/2019

RANDOMIZAÇÃORandomização 1:1

Desfecho Primário de Eficácia: Tempo até 1o AVC / embolia sistêmica / morte CV

Desfechos Secundários: Mortalidade total / sangramento maior / Qualidade de

vida / Função cognitive / custo-efetividade

� Randomizado

� Prospective

� Duplo-cego

ClinicalTrials.gov/NCT02618577


Summary & Concluding remarks


diego duarte alcoba, ph.d. - jotatec and stroke... · documento classificado como...

Documents